biote Corp.
No SEC Form 4 filings for $BTMD in the last 30 days.
Biote (NASDAQ: BTMD) reported Q2 net loss of $7.4M ($0.23/share) versus prior-year net income of $3.9M, and adjusted EBITDA of $5.6M (12.6% margin). Gross margin fell to 65.4% from 71.6% due to higher-cost third-party pellets during a disruption and $600k recall-related costs. Biote cut its 2026 outlook to revenue above $175M and adjusted EBITDA above $25M.
biote Corp. (BTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 btmd-ex99_1.htm EX-99.1 EX-99.1 Biote Reports Second Quarter 2026 Financial Results Continued progress in advancing strategic initiatives Updates full-year outlook Second Quarter 2026 Financial Highlights • Revenue of $44.2 million • Gross profit margin of 65.4% • Net l
Biote Corp. (BTMD) reported its Q1 2026 earnings, with revenue declining 8.3% year-over-year to $44.9 million, falling short of analyst estimates. Despite the revenue miss, diluted EPS of $0.06 surpassed the estimated $0.05. The company also showed tighter liquidity and reduced capital spending, with cash and cash equivalents down 87.2% year-over-year.
Over the past 7 days, alphai's AI scored 2 news stories mentioning BTMD (biote Corp.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent BTMD coverage spans financial news and earnings.
Q2 results and guidance reset the near-term profitability outlook, with margin pressure tied to third-party pellet sourcing and legal costs.
The recall-driven revenue and margin pressure plus guidance revision create a near-term earnings risk and a second-half recovery narrative.
Biote Corp. reported a decline in revenue by 8.3% year-over-year, missing analyst estimates, but achieved a higher-than-expected EPS of $0.06. The company also reduced liquidity and capital expenditure, indicating potential financial strain.
The announcement of the 2026 virtual annual meeting and related corporate governance details are unlikely to cause significant short-term price movements but may influence long-term investor sentiment.
Biote (BTMD) exhibits a negative shareholder equity of -$50.4M and substantial total debt of $107.0M, indicating financial distress. Despite positive EBIT of $35.1M and an interest coverage ratio of 3.2, the negative equity raises concerns about long-term solvency. The current market sentiment is somewhat bearish, with a sentiment score of -0.29721.
alphai scores every news story that mentions BTMD with an AI model for sentiment and relevance, and aggregates insider trades from biote Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biote (NASDAQ: BTMD) reported Q2 net loss of $7.4M ($0.23/share) versus prior-year net income of $3.9M, and adjusted EBITDA of $5.6M (12.6% margin). Gross margin fell to 65.4% from 71.6% due to higher-cost third-party pellets during a disruption and $600k recall-related costs. Biote cut its 2026 outlook to revenue above $175M and adjusted EBITDA above $25M.
6 min readbiote Corp. (BTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 btmd-ex99_1.htm EX-99.1 EX-99.1 Biote Reports Second Quarter 2026 Financial Results Continued progress in advancing strategic initiatives Updates full-year outlook Second Quarter 2026 Financial Highlights • Revenue of $44.2 million • Gross profit margin of 65.4% • Net l
6 min readBiote Corp. (BTMD) reported its Q1 2026 earnings, with revenue declining 8.3% year-over-year to $44.9 million, falling short of analyst estimates. Despite the revenue miss, diluted EPS of $0.06 surpassed the estimated $0.05. The company also showed tighter liquidity and reduced capital spending, with cash and cash equivalents down 87.2% year-over-year.
3 min readBiote Corp. (BTMD) has announced its 2026 annual virtual stockholder meeting for May 12, 2026, where shareholders will vote on electing two Class I directors and ratifying Deloitte & Touche LLP as its independent auditor. The proxy statement also provided details on board composition, corporate governance, and executive and director compensation, including stock option awards and bonuses tied to the company's 2025 performance. Key financial figures and beneficial ownership information were also disclosed.
2 min readThis article provides an overview of biote (BTMD)'s financial health and balance sheet metrics. It highlights key figures such as a negative shareholder equity of $-50.4M and total debt of $107.0M, resulting in a debt-to-equity ratio of -212.4%. The company's EBIT is $35.1M, with an interest coverage ratio of 3.2, and it holds $24.1M in cash and short-term investments.
3 min readImage source: The Motley Fool.Wednesday, November 5, 2025 at 5:00 p.m. ETChief Executive Officer - Bret ChristensenContinue reading ...
3 min readbiote Corp. (BTMD) delivered earnings and revenue surprises of +340.00% and +0.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
4 min readbiote Corp. (BTMD) delivered earnings and revenue surprises of +66.67% and -1.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 min readbiote Corp. (BTMD) delivered earnings and revenue surprises of 33.33% and 3.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min read
